Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
In Vivo Gene Editing of Human Hematopoietic Stem and Progenitor Cells Using Envelope-Engineered Virus-Like Particles
[Nature Biotechnology] Scientists designed and tested two different virus-like particles envelopes for human hematopoietic stem and progenitor cells editing in vitro and in vivo.
Ace2 Safeguards Embryonic Hematopoietic Stem and Progenitor Cell Production by Restraining Nlrp3-Mediated Pyroptosis
[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified angiotensin-converting enzyme 2 (Ace2), a key component of renin–angiotensin system, as a crucial anti-inflammatory regulator of embryonic hematopoiesis in zebrafish and mice.
CD9, a Tetraspanin in Cancer: Biology, and Therapeutic Promise in Acute Leukemia
[Oncogenesis] Scientists review the tetraspanin family and summarize current knowledge on CD9 regulation and function across cancers, with a focus on leukemia
Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia
[Cancer Discovery] Scientists investigated how hematopoietic stem cell developmental stages affect leukemic transformation, disease progression, and therapy response using a novel, humanized model of NUP98::NSD1-driven pediatric AML that is particularly aggressive with WT1 comutations.
Chromatin Accessibility in Stem Cells Unveils Progressive Transcriptional Alterations in Myelodysplastic Syndrome
[Nature Communications] Researchers showed that the chromatin accessibility profiles of myelodysplastic syndrome stem cells more accurately reflect disease status than those of progenitor cells and reveal the process of stem cell alterations during disease progression.
Leveraging the Active Conformation of LFA-1 As a Potential Target for Hematological Malignancies
[Molecular Therapy-Methods & Clinical Development] The authors introduced a novel nano-liposomal delivery system that exploits the overexpressed, open-active conformation of Lymphocyte Function-Associated Antigen-1 (LFA-1) on malignant hematopoietic cells.
Inhibiting Ferroptosis Enhances Ex Vivo Expansion of Human Hematopoietic Stem Cells
[Nature Cell Biology] Scientists showed that HSC loss in existing culture methods is driven largely by ferroptosis, a metabolically regulated, iron-dependent cell-death pathway, and that it can be blocked to augment HSC expansion.
MAFB Regulates Hematopoietic Stem Cell Proliferation and Maintenance
[Scientific Reports] Using Mafb-deficient and Mafb-GFP knock-in mouse models, researchers demonstrated that Mafb deletion enhances proliferation, cell cycle entry, and myeloid differentiation of fetal liver HSCs.
Erythroid Precursors Regulate Local Oxygen Tension and Repair Outcomes in the Bone Marrow Niche
[Proceedings of The National Academy of Sciences of The United States of America] Investigators showed in mice that while the tissue oxygen tension in bone marrow is low, intracellular oxygenation is heterogeneous, and erythroid cells are high in oxygen.
CBX7 Regulates Chemotherapy-Induced Senescence-Like Growth Arrest in Multiple Myeloma via the ERK/STAT3/PIM1 Axis
[Journal of Translational Medicine] Flow cytometry assessed senescence-associated β-galactosidase activity in myeloma cells from bone marrow samples of multiple myeloma patients.
Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase II Pivotal Cohort
[Journal of Hematology & Oncology] 5-year data support the durable efficacy and manageable safety profile of olutasidenib in relapsed/refractory mutant isocitrate dehydrogenase 1 (mIDH1) AML, including heavily pretreated patients.
FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia with a NPM1 Mutation
[US FDA] The FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory AML with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
